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What are the new findings?
 ► The effect of taking omega-3 polyunsaturated fatty 
acid (PUFA) supplements on disability and pain out-
comes in people with rotator cuff related shoulder 
pain (RCRSP) is no greater than placebo.
 ► Change in self-reported pain and disability scores 
was similar between groups over all outcome points 
and is linked to the exercise intervention (or anoth-
er mechanism such as natural improvement) rather 
than omega-3 PUFA supplements.
 ► Further research is warranted to determine whether 
higher doses, longer duration doses or earlier inter-
vention of omega-3 PUFA regimes would influence 
disability and function in RCRSP.
How might it impact on clinical practice in the near 
future?
 ► Clinicians can be confident that class and home ex-
ercise prescription without the addition of omega-3 
PUFA supplements provides improvement in func-
tion and reduction in pain over time in those pre-
senting with RCRSP.
AbsTrACT
study design Multicentre, double-blind, placebo-
controlled randomised clinical trial.
Objectives To compare the effectiveness of long chain 
omega-3 polyunsaturated fatty acids (PUFAs) as part of the 
management for people diagnosed with rotator cuff related 
shoulder pain (RCRSP).
summary of background Although there is no robust 
evidence to support their use, omega-3 PUFAs have been 
recommended for those with tendinopathy due to their 
potential to moderate inflammation.
Methods Participants with RCRSP (n=73) were 
randomised to take either nine MaxEPA capsules providing 
1.53 g eicosapentaenoic acid, 1.04 g docosahexaenoic 
acid or nine matching placebo capsules containing 
oleic acid per day for 8 weeks. In addition, participants 
attended an exercise/education programme for 8 weeks. 
Participants were assessed at prerandomisation, 8 weeks 
(primary outcome point), 3 months, 6 months and 12 
months (secondary outcome point). Primary outcome was 
the Oxford Shoulder Score (OSS). Secondary outcomes 
included the Shoulder Pain and Disability Index (SPADI), 
Patient Specific Functional Score, Euro Qol 5D-3L, 
Short Form 36, global rating of change and impairment 
measurements. Analysis was by intention to treat.
results Difference in the change in the OSS between 
the two groups at 2 months was –0.1 (95% CI −2.6 to 
2.5, p=0.95). The change in SPADI scores was −8.3 
(95% CI −15.6 to −0.94, p=0.03, analysed by analysis of 
covariance adjusted for baseline) at 3 months.
Conclusion  Omega-3 PUFA supplementation may have a 
modest effect on disability and pain outcomes in RCRSP.
InTrOduCTIOn
Rotator cuff related shoulder pain (RCRSP) 
is characterised by pain and dysfunction 
arising from one or more of the rotator cuff 
tendons1 and maybe associated with long-
term morbidity and functional loss. The 
reported life time incidence of RCRSP may 
reach 67%2 3 and the annual incidence over 
1%.4 5 Many continue experiencing pain and 
functional disability for up to 1 year,6–8 and 
over 50% of individuals experience continued 
pain after 3 years.9
Much is still unknown about the patho-
physiology and management of RCRSP. 
One hypothesis considers involvement of 
inflammation in the pathoaetiology and 
symptomology.10 The accumulation of inflam-
matory cells in human tendons11–13 and in 
animal models,14 15 coupled with increased 
levels of proinflammatory cytokines evident 
in tendinopathic rotator cuff tissue,16–18 
may support this hypothesis. Advice, educa-
tion and graduated exercise forms the main 
RCRSP management, and although demon-
strate equivalent outcomes to surgery,19 20 
incomplete symptom resolution is common. 
Subsequently, other interventions must be 
considered.
The rationale underpinning fish oil 
supplementation in RCRSP lies in the 
anti-inflammatory effects of omega-3 
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polyunsaturated fatty acids (PUFAs).21 While omega-3 
PUFAs have been found to have beneficial effects on a 
range of inflammatory conditions,22 the results cannot be 
directly translated to RCRSP.
Two previous trials have reported conflicting findings 
regarding efficacy of omega-3 PUFAs for tendinopathy 
treatment.23 24 While the potential for dietary supple-
mentation of omega-3 PUFAs and antioxidants to 
reduce disability and morbidity associated with RCRSP is 
appealing, it has not yet been formally investigated.21
The primary aim of this RCT was to assess whether 2 
months supplementation with omega-3 PUFAs combined 
with exercise, conferred any benefit (measured by pain 
reduction and improved disability and function) over 
a placebo and the same exercise programme in RCRSP 
management.
MATerIAls And MeTHOds
design
Multicentre, two armed, double-blind, randomised 
placebo controlled clinical trial (ISRCTN17856844).
Seventy-three participants were recruited from three 
secondary care and one primary care National Health 
Service (NHS) physiotherapy departments in London, 
UK. Inclusion criteria include 18–80 years, a 3-month or 
greater history of unilateral shoulder pain, pain produced 
or increased during shoulder flexion and/or abduction 
and/or external rotation of the symptomatic shoulder 
and a minimum of four of the following: positive Neer’s 
impingement sign, positive Hawkins and Kennedy test, 
pain and weakness reproduced on full and/or empty can 
test, pain and weakness on resisted shoulder external rota-
tion and pain on palpation over greater tuberosity of the 
humerus. Exclusion criteria include allergy/ unwilling 
to take fish oils or currently taking over 1 g/day of fish 
oils, diabetes, pregnancy or breast feeding, reproduction 
of shoulder symptoms during active cervical spine move-
ments, post-traumatic onset of symptoms, radiographic 
or clinical evidence of shoulder instability (sulcus, ante-
rior/posterior draw, relocation test, apprehension test).
Patient involvement
Patients were involved in outcome measure selection and 
burden of the assessment. Patients were not involved at 
the study design stage or in the recruitment or conduct 
of the study. A one-page synopsis of the study results will 
be disseminated to the participants via mail or email.
Consent and randomisation
Participants provided written informed consent prior 
to study enrolment and were randomly assigned using 
predetermined computer-generated codes into allocated 
groups. Concealment to group allocation was via serially 
numbered opaque envelopes, produced by a third party 
who held the randomisation codes. The chief investigator 
and participants remained blind to group allocation for 
study duration until all data had been entered into the 
statistical database.
Intervention
MaxEPA (Seven Seas Ltd, Hull, UK, MHRA product 
licence 19488/0353) soft shell capsules containing 170 
mg eicosapentaenoic acid (EPA), 115 mg docosahex-
aenoic acid (DHA) and 2 units/g tocopherols acetate 
(vitamin E) were provided. The placebo supplement was 
identical in appearance and contained a mixed inert oil 
(olive oil BP containing the same amount of vitamin E 
and antioxidants as the active treatment), EPA and DHA 
being replaced by oleic acid. Both group’s participants 
were asked to take nine capsules daily for 2 months and 
recommended to take the capsules with meals to mini-
mise any gastrointestinal irritation. Participants were 
requested to return any unused capsules at the end of 
the study.
All participants attended weekly, hour long RCRSP 
exercise and education groups, for 8 weeks.
The exercises aimed to improve strength and senso-
rimotor control of the shoulder and included lower limb 
exercises. Physiotherapists delivered manual therapy 
shoulder techniques, determined pragmatically based on 
what was considered most appropriate for approximately 
1 min.
Participants were assessed by the chief investigator 
or research assistant at baseline, 8 weeks, 3 months, 6 
months and 1 year.
Outcome measures completed included:
1. Disability: Oxford Shoulder Score (OSS) and Shoulder 
Pain and Disability Index (SPADI).
2. Pain: Numerical Rating Scale (NRS) and Short Form 
(SF) 36 bodily pain (BP) domain.
3. Quality of life: SF 36 and Euro Qol 5D-3 L.
4. Function: Patient Specific Functional Score (PSFS).
5. Global perception of change score.
6. Impairment measures; shoulder range of motion and 
strength.
Plasma fatty acids, capsules returned and self-report 
numbers of capsules taken were used as measures of 
adherence with the supplement intervention. Exercise 
class attendance and documentation of home exercises 
undertaken gave an indication regarding adherence with 
exercise intervention.
Sample size calculations were based on a change in OSS 
as the primary outcome. When designing the study, the 
minimal clinically important difference was not published 
for the OSS, but from previous work,25 it was estimated 
to be five which is equivalent to a 21% change from the 
midpoint of the scale (0–48). A change of six has recently 
been shown to be the minimal important difference and 
smallest detectable change for the OSS.26 The SD of the 
OSS is 5.87.25 The sample size was calculated to be 29 
subjects in each of the two groups (58 in total), to detect 
a five-point change at p<0.05 with a 90% power. Allowing 
for a dropout rate of 10%,6 the study aimed to randomise 
32 participants to each group.
Adverse events were defined as intervention side effects 
requiring medical intervention.
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Table 1 Participant demographic data
Variable
Placebo 
(n=35)
Treatment 
(n=38)
Gender: male 20 (57.1%) 17 (44.7%)
Age (years) 52.0 (16.2) 52.2 (12.0)
Body mass index (kg/m²) 28.9 (8.4) 27.5 (5.2)
Waist circumference (cm) 98.8 (16.4) 94.8 (13.0)
Current smoker 5 (14.3%) 5 (14.3%)
Plasma eicosapentaenoic acid 
and docosahexaenoic acid 
(wt%)
3.9 (1.5) 4.1 (1.8)
Analgesia medication 10 (28.6%)* 3 (7.9%)
Statin medication 7 (20%) 6 (15.8%)
Symptom duration (months) 10 (4–18) 9 (6–19.5)
Mechanism of injury 
  Insidious 17 (48.6%) 21 (55%)
  Accident/fall 5 (14.3%) 8 (21.1%)
  Lifting/repetitive movement 6 (17.1%) 6 (15.8%)
  Exercise 7 (20.0%) 3 (7.9%)
Able to sleep on symptomatic 
shoulder
17 (48.6%) 17 (44.7%)
Summary measures represent means/N (SD/%/range). Differences 
between groups test with Mann-Whitney test or χ2 test.
*P=0.03
wt%, weight percentage.
statistical analysis
Statistical analysis of the data was conducted using SPSS 
for windows V.22.0 (IBM Software, Hampshire, UK). 
Standard distributional checks were made, and where 
appropriate, analyses were attempted following log trans-
formation.
The data was analysed on an intention-to-treat basis. 
Analysis of covariance (ANCOVA) tests were conducted 
for within-subject factor (assessment time point) and 
between-group factor (supplement type; placebo or treat-
ment) with OSS as the dependent variable, the treatment 
allocation as the predictor factor, age, gender and body 
mass index as covariates and the baseline OSS as an offset 
variable. A mixed-model ANCOVA analysis was also used 
to look for change over the whole study period in each 
outcome measure adjusting for the baseline measure-
ments. Similar analyses were conducted for secondary 
outcomes efficacy analysis: ANCOVA and mixed-model 
ANCOVA.
resulTs
Seventy-three participants were consented between 
December 2008 and January 2013, when precalculated 
sample reached. More participants in the placebo group 
reported use of analgesic medication (p=0.02; χ2 test). 
There were no other significant differences in baseline 
characteristics or outcome measures between groups 
(table 1).
At the primary outcome point at 2 months, 71 (96%) 
participants were reassessed, and at 12 months, 65 (89%) 
participants were reassessed. There was no statistically 
significant difference in the attrition rate between groups 
(figure 1).
Adherence to the interventions
No significant difference in intervention adherence was 
found between groups. There was a statistically signif-
icant difference in the blood plasma levels of omega-3 
PUFAs (EPA and DHA) at the end of the intervention 
between the two groups (mean difference=2.4, 95% CI 
1.6 to 3.1, p<0.001) (figure 2).
Both groups demonstrated a significant reduction in 
disability, as measured by the OSS. There was on average 
a 25% reduction in disability (95% CI 15.3 to 34.6; mean 
difference=8.2) in the placebo group and 25% reduction 
(95% CI 13.5 to 36.2; mean difference=6.7) in the inter-
vention group at 2 months (table 2).
No statistically significant difference was found in the 
change in the primary outcome, OSS, between the two 
groups at 2 months (adjusted mean difference=−0.1, 95% 
CI −2.6 to 2.5, p=0.95) and up to 12 months (adjusted 
mean difference=−0.3, 95% CI −3.3 to 2.6, p=0.82) 
(table 2, figure 3).
A statistically significant reduction in level of perceived 
disability as measured by SPADI was observed in both 
groups (2 months: placebo mean difference=16.9, 
95% CI 10.9 to 22.9, p=0.00 and omega-3 PUFA mean 
difference=15.9, 95% CI 9.5 to 22.2, p=0.00; 12 months: 
placebo mean difference=15.7 95% CI 8.2 to 23.3, p=0.00 
and omega-3 PUFA mean difference=7.8, 95% CI 0.9 to 
14.71, p=0.03).
The PUFA supplement group showed a statistically 
significant change when compared with the placebo 
group (adjusted mean difference=−8.6, 95% CI –15.6 to 
–0.9, p=0.03, analysed by ANCOVA adjusted for baseline) 
at 3 months (table 2, figure 4).
A statistically significant reduction in pain was reported 
by both groups at the primary outcome point (NRS 
(p<0.01) and the SF 36 BP (p<0.01) component). At 2 
months, the placebo group demonstrated a 2.2 point 
reduction (95% CI 1.2 to 3.1), and the omega-3 PUFA 
group demonstrated a 2.1 point reduction (95% CI 0.04 
to 2.3) in the NRS.
No statistically significant differences were found 
between the groups for the secondary outcomes when 
compared at any follow-up point (table 2 and table 3).
There were significant differences found in shoulder 
abduction and flexion range of motion between the two 
groups (p<0.01) in favour of the treatment group (flexion 
mean difference=7.7°, 95% CI 2.4 to 12.9, abduction 
mean difference=10.4°, 95% CI 3.1 to 17.7). These differ-
ences may not be clinically important. Shoulder external 
rotation strength at 12 months was also found to be statis-
tically significantly different between groups in favour of 
the treatment group (p<0.01).
copyright.
 o
n
 19 O
ctober 2018 by guest. Protected by
http://bmjopensem.bmj.com/
BM
J O
pen Sport Exerc M
ed: first published as 10.1136/bmjsem-2018-000414 on 19 October 2018. Downloaded from 
4 Sandford FM, et al. BMJ Open Sport Exerc Med 2018;4:e000414. doi:10.1136/bmjsem-2018-000414
Open access
Figure 1 Consort diagram.
There were no statistically significant differences in 
pretrial and post-trial fatty acid intakes for the partici-
pants (estimated from 4-day food diaries).
No serious adverse events were reported.
A post hoc analysis of the effect of increased EPA and 
DHA within the plasma and the improvement in disability 
and pain at the primary outcome point of 2 months using 
regression and partial correlations adjusted for treatment 
group was conducted. A relationship between increasing 
EPA and DHA plasma levels and decreasing reported 
pain as measured by the NRS was found (correlation 
−31% for EPA and 32% for DHA, p=0.01 for both EPA 
and DHA). For each unit increase of EPA and DHA, 
there was on average a 9% and 14% change observed in 
the NRS score, respectively.
dIsCussIOn
This study investigated the efficacy of omega-3 PUFA 
supplements alongside an exercise intervention for 
RCRSP. Study results demonstrated statistically and clin-
ically significant improvements in disability and pain 
in both group’s participants at 2, 3, 6 and 12 months. 
The omega-3 PUFA group demonstrated a more rapid 
improvement in disability of 64% improvement from 
baseline at 3 months, compared with a 42% in the 
placebo group on secondary outcome measure (SPADI). 
However, no discernible difference was noted between 
the two groups in OSS and NRS scores and so may be an 
anomaly, further investigation would be indicated.
Two previous randomised controlled trials investi-
gating the efficacy of omega-3 PUFA supplements and 
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Figure 2 Graph showing the rise in EPA and DHA plasma levels within the treatment group, within group comparisons made 
using a paired samples t-test. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; wt%, percentage weight; ∆, mean 
difference and 95% CI between baseline and follow-up.
tendinopathies were identified.23 24 Mavrogenis et al’s 
double-blinded study reported a significant improvement 
in pain after 32 days of supplementation with omega-3 
PUFA and an antioxidant pill in recreational athletes 
with tendinopathies.21 However, methodological limita-
tions included participant selection bias, an absence of 
intention to treat27 and broad inclusion criteria. Poor 
clarity surrounding confounding factors, including the 
implications of using ultrasound in treatment packages 
further limited the potential impact of findings.
Roe et al, using an omega-3 PUFA supplement and 
antioxidant pill for 56 days on subjects with lateral elbow 
tendinopathy, found no statistically significant differ-
ences in pain at either week 8 or 24. Methodological 
differences between the three studies may explain the 
discrepancies in the outcomes and conclusions. Mavro-
genis et al23 did not use an intention-to-treat analysis, and 
23% of subjects were excluded. Furthermore, the mean 
duration of symptoms reported by Mavrogenis et al23 was 
6 months compared with the current study (9 months) 
and that of Roe et al (18 months). Poorer outcomes are 
associated with longer duration of symptoms,28 raising 
the possibility that supplementation at an earlier stage 
may be of greater benefit. This is purely speculative, and 
the hypothesis requires testing. Additionally, all studies 
involved different treatments in the experimental groups.
No study included a non-treatment control group. 
Therefore, the improvements in reported disability may 
be due to regression to the mean,29 the immediate or 
longer term effects of exercise, other treatments or the 
immediate or longer term influence of the supplements.
The dosage of 2.6 g omega-3 PUFA per day was lower 
than the 5.1 g in the studies conducted both by Mavro-
genis et al23 and Roe et al. While positive effects were 
noted at that dose given in the Mavrogenis et al’s23 exper-
imental group, similar outcomes were not reported by 
Roe et al, indicating the positive outcome in the Mavro-
genis et al’s23 study cannot be explained by dosage alone. 
Omega-3 PUFA (2.6 g) was selected in the present study 
based on the lower predicted efficacy level of omega-3 
PUFA in the previous trials.30
The relationship observed in this study with EPA and 
DHA and pain (as measured by NRS) supports the argu-
ment of investigating the efficacy of higher doses of 
omega-3 PUFA.
Adherence to the intervention was good; capsules 
returned matched reported consumption and signif-
icant increases in the proportions of EPA and DHA in 
plasma lipids provide independent verification. There 
were, however, considerable variations in the extent of 
the increases in EPA and DHA within the participants 
allocated to the intervention group possibly reflecting 
different body sizes and other fatty acids, particularly 
omega-6 fatty acids, in their background diet. The 
increases in EPA and DHA are comparable with other 
studies that have used intakes of omega-3 PUFA in the 
range of 2–3 g/d.31 MaxEPA which was used in the 
present study contains in total approximately 35% long-
chain omega-3 fatty acids (including 18:4 n−3, 20:4 n−3, 
22:5 n−3), with EPA and DHA typically providing 18% 
and 12% of the fatty acids. Allowing for the non-fatty acid 
components, the calculated intake of total long-chain 
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Table 2 Outcome measures during the course of the trial
Outcome measure
Intervention group
Placebo
Omega-3 
polyunsaturated 
fatty acids
Disability (Oxford Shoulder Score, 0–48; 48 best)
  Baseline 31.7 (28.9 to 34.5) 32.0 (29.5 to 34.5)
  2 months 39.9 (37.5 to 42.4) 38.7 (36.1 to 41.3)
  3 months 39.5 (37.1 to 41.8) 40.5 (37.9 to 43.1)
  6 months 42.1 (40.4 to 43.8) 41.6 (39.2 to 44.1)
  12 months 43.1 (41.2 to 45.0) 43.0 (40.7 to 45.4)
Disability (Shoulder Pain and Disability Index, 0–100; 
0=best)
  Baseline 43.1 (21.5) 38.7 (22.3)
  2 months 25.1 (22.8) 23.4 (23.1)
  3 months 25.3 (21.1) 13.9 (18.1)*
  6 months 16.9 (18.3) 13.3 (19.0)
  12 months 9.9 (2.4) 11.2 (19.2)
Function (Patient Specific Functional Score 0–100; 100 
best)
  Baseline 38.4 (31.8 to 44.9) 36.8 (30.3 to 43.3)
  2 months 58.4 (50.2 to 66.6) 64.6 (56.8 to 72.3)
  3 months 68.9 (61.0 to 76.8) 72.0 (64.6 to 79.5)
  6 months 72.9 (65.3 to 80.5) 76.6 (69.3 to 83.8)
  12 months 78.8 (70.6 to 87.0) 80.4 (73.0 to 87.9)
Pain (Numerical Rating Scale, 0–10; 0=best)
  Baseline 6.3 (5.7 to 6.9) 6.0 (5.3 to 6.7)
  2 months 4.0 (3.2 to 4.8) 3.8 (2.9 to 4.6)
  3 months 3.5 (2.6 to 4.4) 2.6 (1.8 to 3.3)
  6 months 3.3 (2.3 to 4.3) 2.9 (2.0 to 3.7)
  12 months 2.1 (1.3 to 2.9) 2.1 (1.2 to 3.0)
Pain (Short Form 36 bodily pain, 0–100; 100=best)
  Baseline 47.9 (41.6 to 54.2) 51.6 (44.7 to 58.5)
  2 months 64.7 (57.8 to 71.5) 67.3 (61.4 to 73.2)
  3 months 62.2 (55.1 to 69.4) 71.1 (64.3 to 77.8)
  6 months 73.4 (66.8 to 79.9) 74.5 (67.0 to 81.9)
  12 months 69.6 (61.9 to 77.3) 80.2 (73.5 to 86.9)
Quality of Life (EQ-5D-3L, −0.5 to 1.0; 1=best)
  Baseline 0.7 (0.6 to 0.8) 0.7 (0.6 to 0.8)
  2 months 0.7 (0.7 to 0.8) 0.8 (0.7 to 0.9)
  3 months 0.8 (0.7 to 0.8) 0.8 (0.8 to 0.9)
  6 months 0.8 (0.7 to 0.9) 0.8 (0.8 to 0.9)
  12 months 0.8 (0.8 to 0.9) 0.9 (0.8 to 0.9)
Visual Analogue Scale for quality of life (EQ-5D-3L, 0–100; 
100=best)
  Baseline 72.9 (68.3 to 77.5) 70.2 (64.1 to 76.4)
  2 months 78.3 (73.5 to 82.0) 80.2 (76.3 to 84.1)
  3 months 79.3 (75.2 to 83.5) 82.4 (77.4 to 87.4)
Continued
Outcome measure
Intervention group
Placebo
Omega-3 
polyunsaturated 
fatty acids
  6 months 82.8 (79.5 to 86.0) 82.2 (78.0 to 86.3)
  12 months 78.7 (71.3 to 86.0) 79.1 (73.4 to 84.9)
Global perception of change (0–100; 100=best)
  2 months 54.1 (43.8 to 64.4) 55.3 (45.4 to 65.2)
  3 months 66.1 (58.3 to 74.0) 70.8 (61.9 to 79.7)
  6 months 75.6 (68.2 to 82.9) 74.2 (63.2 to 85.2)
  12 months 80.0 (72.2 to 87.8) 78.0 (66.9 to 89.1)
Summary measures are means (95% CIs) analysed using 
independent samples t-test and between-group comparison by 
univariate analysis of covariance adjusted for baseline value, age, 
gender and body mass index.
*Represents a statistically significant difference
Table 2 Continued
Figure 3 Oxford Shoulder Score (OSS) at each assessment 
point. Error bars=95% CI.
omega-3 fatty acids would be close to 3 g/day, the level 
where triglyceride lowering effects are noted as well as 
effects on blood pressure. With allowance for incom-
plete consumption (eight vs nine capsules/day), this 
still would provide a total intake of 2.7 g/day of omega-3 
fatty acids. While higher intakes of omega-3 might have 
greater anti-inflammatory effects, the safety of higher 
intakes taken for long periods of time is less established.
lIMITATIOns
Two months supplementation was selected due to 
evidence suggesting that there is a maximal incorpora-
tion into the plasma phospholipids at 4 weeks.32 33 The 
positive results reported by Mavrogenis et al23 were seen 
at 32 days, which was half the duration of the intervention 
and first outcome point of the current study. However, 
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Figure 4 Shoulder Pain and Disability Index (SPADI) at each assessment point. Error bars = 95% CI.
in trials of omega-3 PUFAs for rheumatoid arthritis and 
osteoarthritis, supplementation duration can last up to 6 
months. It is not possible to say whether ongoing supple-
mentation or a higher dose would have afforded any 
additional benefit in this study.
Improvement in disability associated with attendance 
to the exercise group may have overshadowed any 
change in disability directly associated with omega-3 
PUFA supplement use. However, a well-structured exer-
cise programme is current best practice intervention for 
RCRSP1 and subsequently potentially unethical to with-
draw this intervention.
Possibly that the OSS was not sensitive enough to detect 
any change attributable to the omega-3 PUFA supple-
ments. A statistically significant difference in reduction 
in disability (as measured by SPADI) was seen at 3 months 
but not mirrored in the OSS. This is despite reported 
good correlation between the OSS and SPADI (correla-
tion coefficient=0.85) and good agreement between the 
scores (weighted kappa=0.79).34 The recall period of 
the two questionnaires may explain the difference. The 
SPADI asks the respondent to recall symptoms during the 
past week, whereas the OSS asks the respondent to recall 
symptoms over the past 4 weeks. Between the primary 
outcome point at 2 months and the subsequent follow-up 
at 3 months, there was only a 4-week break. It is possible 
that any additional benefit experienced between 2 and 
3 months was not recorded by the OSS due to the dura-
tion of the recall period. Although questionable whether 
a difference of 8.25 observed between the groups in the 
SPADI at 3 months is clinically meaningful when the 
minimal clinically important difference (MCID) of the 
SPADI has been reported to range from 8 to 20.35–38 Simi-
larly, this finding may have occurred by chance, especially 
as the difference was not sustained.
Assessments were carried out by more than one exam-
iner which may have introduced measurement error. 
The intertester reliability of the impairment measures 
by the examiners was found to be adequate (table 3).39 
As for the SPADI, the primary outcome measure was the 
OSS, a self-administrated questionnaire, and as such, it is 
unlikely that the results would be influenced by a change 
in the examiner.
COnClusIOn
The findings of this randomised placebo controlled trial 
suggest that an exercise program combined with 9 g/
day (2.6 g EPA and DHA) of omega-3 PUFA for 8 weeks 
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Table 3 Impairment measures during the course of the trial
Outcome 
measure
Intervention group
Placebo
Omega-3 polyunsaturated 
fatty acid
Symptomatic GHJ flexion (measured in degrees)
  Baseline 141.1 (134.2 to 148.0) 140.4 (134.6 to 146.2)
  2 months 144.5 (137.9 to 151.1) 145.2 (139.1 to 151.3)
  3 months 146.6 (142.0 to 151.2) 152.8* (148.6 to 157.0)
  6 months 150.6 (144.9 to 156.3) 151.1 (145.6 to 156.6)
  12 months 149.7 (144.9 to 154.5) 151.7 (145.8 to 157.6)
Symptomatic GHJ abduction (measured in degrees)
  Baseline 134.6 (125.2 to 144.0) 131.5 (122.6 to 140.4)
  2 months 144.3 (137.4 to 151.2) 138.1 (130.3 to 145.9)
  3 months 140.4 (133.5 to 147.3) 148.4* (144.0 to 152.8)
  6 months 149.2 (142.9 to 155.5) 148.1 (142.2 to 154.0)
  12 months 146.1 (139.7 to 152.5) 150.8 (145.3 to 156.3)
Symptomatic GHJ external rotation (measured in cm)
  Baseline 41.1 (39.2 to 43.0) 39.3 (37.4 to 41.2)
  2 months 41.4 (39.4 to 43.3) 40.5 (39.0 to 42.1)
  3 months 42.0 (39.6 to 44.4) 41.9 (39.9 to 43.9)
  6 months 42.4 (40.1 to 44.7) 40.6 (38.2 to 43.0)
  12 months 44.0 (42.0 to 46.0) 42.4 (40.5 to 44.3)
Symptomatic GHJ hand behind back (measured in cm)
  Baseline 31.0 (27.6 to 34.4) 30.8 (26.9 to 34.7)
  2 months 28.3 (24.8 to 31.8) 28.6 (22.9 to 28.7)
  3 months 27.5 (24.0 to 31.0) 25.8 (22.6 to 29.0)
  6 months 26.2 (23.3 to 29.0) 24.6 (22.4 to 26.8)
  12 months 24.8 (21.2 to 28.4) 23.4 (20.8 to 26.0)
Symptomatic GHJ flexion strength (measured in pounds)
  Baseline 21.6 (19.6 to 23.6) 21.1 (17.7 to 24.5)
  2 months 24.5 (22.1 to 26.9) 22.8 (19.4 to 26.2)
  3 months 25.2 (22.6 to 27.8) 22.1 (18.5 to 25.7)
  6 months 27.1 (24.4 to 29.6) 26.4 (22.6 to 30.2)
  12 months 26.6 (23.6 to 29.6) 25.6 (27.2 to 29.0)
Symptomatic GHJ abduction strength (measured in pounds)
  Baseline 21.6 (18.6 to 24.6) 19.3 (16.6 to 22.0)
  2 months 25.7 (22.7 to 28.7) 22.4 (19.2 to 25.6)
  3 months 25.6 (22.3 to 28.9) 22.3 (18.9\ to 25.7)
  6 months 26.7 (24.1 to 29.3) 24.9 (21.7 to 28.1)
  12 months 27.6 (25.0 to 30.2) 27.2 (23.7 to 30.7)
Symptomatic full can strength (measured in pounds)
  Baseline 9.4 (7.6 to 11.2) 8.3 (6.4 to 10.2)
  2 months 11.4 (9.4 to 13.4) 10.2 (7.8 to 12.6)
  3 months 12.2 (10.0 to 14.4) 10.8 (8.1 to 13.5)
  6 months 12.4 (10.3 to 14.5) 11.7 (9.3 to 14.1)
  12 months 13.0 (11.2 to 14.8) 12.6 (10.2 to 15.0)
Symptomatic empty can strength (measured in pounds)
  Baseline 9.1 (7.6 to 10.6) 7.5 (5.8 to 9.2)
  2 months 11.8 (10.0 to 13.6) 10.3 (8.1 to 12.5)
  3 months 12.6 (10.7 to 14.5) 9.9 (7.6 to 12.2)
Continued
Outcome 
measure
Intervention group
Placebo
Omega-3 polyunsaturated 
fatty acid
  6 months 13.1 (11.3 to 14.9) 11.5 (9.3 to 13.7)
  12 months 14.3 (11.5 to 17.1) 12.8 (10.6 to 15.0)
Symptomatic external rotation strength (measured in pounds)
  Baseline 15.4 (13.3 to 17.5) 12.7 (10.8 to 14.6)
  2 months 16.8 (14.8 to 18.8) 15.6 (13.2 to 18.0)
  3 months 17.8 (15.5 to 20.1) 16.2 (13.5 to 18.9)
  6 months 18.7 (16.6 to 20.8) 16.7 (14.3 to 19.1)
  12 months 17.8 (15.9 to 19.7) 18.7* (16.3 to 21.1)
Symptomatic internal rotation strength (measured in pounds)
  Baseline 19.2 (16.5 to 21.9) 16.9 (14.3 to 19.5)
  2 months 22.1 (20.1 to 26.1) 19.1 (15.9 to 22.3)
  3 months 23.8 (20.4 to 27.2) 21.4 (17.5 to 25.3)
  6 months 24.3 (20.8 to 27.8) 20.7 (17.1 to 24.3)
  12 months 24.6 (21.5 to 27.7) 23.1 (19.4 to 26.8)
Symptomatic elbow flexion strength (measured in pounds)
  Baseline 26.7 (21.8 to 31.6) 25.2 (20.4 to 30.0)
  2 months 31.3 (26.7 to 35.9) 29.4 (24.2 to 34.6)
  3 months 32.9 (27.6 to 38.2) 30.3 (24.1 to 36.5)
  6 months 32.6 (27.9 to 37.3) 33.0 (27.5 to 38.5)
  12 months 33.3 (27.4 to 39.2) 31.7 (26.3 to 37.1)
Summary measures are means (95% CIs) analysed using independent 
samples t-test and between-group comparison by univariate analysis 
of covariance adjusted for baseline value, age, gender and body mass 
index.
*represents a statistically significant difference
GHJ, Gleno humeral joint.
Table 3 Continued
provides no additional benefit when compared with the 
same exercise program when combined with a placebo 
supplement over the course of one year, for those diag-
nosed with RCRSP. The finding that at 3-months a 
significant reduction in disability (as measured by the 
SPADI) in the omega-3 group warrants further investi-
gation, but this finding does not currently support the 
use of omega-3 PUFA supplementation in this condi-
tion. With acknowledged limitations, such as no control 
group, the findings of this investigation suggest participa-
tion in a graduated exercise program is associated with 
a substantial reduction in disability and improvement in 
function for people diagnosed with RCRSP.
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